Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Arcturus org - The Untold Story

Cathie Wood Adds 48K Shares to This Under-the-Radar Growth Play

Wood trimmed stakes in Nvidia, Meta, and Tesla; instead, she added this speculative biotech play.

This AI tech creates a 3D map of sports fields in real-time, enabling you to put a virtual camera anywhere. Surely I’m not the only creative who’s worried?

This AI tech creates a 3D map of sports fields in real-time, enabling you to put a virtual camera anywhere. Surely I’m not the only creative who’s worried?

Arcturus Stage creates a 3D map of a sports field in real time, but how will this impact creatives and the wider human element of sports broadcasts?

Digital Camera World

1 Under-$10 Stock Set to Surge as Much as 963% in 2026

1 Under-$10 Stock Set to Surge as Much as 963% in 2026

The high price estimate for Arcturus suggests the stock can rally as high as 963%. Is it a far-fetched target?

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Residents in rural Greece struggle as bears and wolves make a remarkable comeback

There has been a rapid increase in the number of one-on-one encounters between humans and wild animals even in residential areas

2 Stocks to Buy Under $10 That Wall Street Loves

While penny stocks are risky, they also have the potential to deliver outsized gains.

Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock was trading lower on Wednesday after the company shared interim results from its ongoing Phase 2 trial of ARCT-032, an investigational inhaled mRNA therapy for cystic fibrosis.

2 Growth Stocks to Buy Now With 367% to 410% Upside

Strong, innovative pipelines make these two biotech firms smart buys now.

inkl

Read news from The Economist, FT, and more,
with one subscription

Eight cases of new Covid variant Arcturus identified in Wales

Eight cases of new Covid variant Arcturus identified in Wales

The data shows five people have died with the new variant

5 people die in UK from Arcturus Covid strain that has spread around world

5 people die in UK from Arcturus Covid strain that has spread around world

It has led to face mask rules being re-introduced elsewhere in the world

Nottingham Post

New Covid Arcturus variant causing surge of coronavirus cases in India detected in UK

New Covid Arcturus variant causing surge of coronavirus cases in India detected in UK

The XBB.1.16. strain has now been detected in at least 22 countries

Manchester Evening News

CSL paying $312m to license mRNA vax tech

CSL paying $312m to license mRNA vax tech

CSL Seqirus is paying $A312 million up-front to license next-generation mRNA technology from a small US company, Arcturus Therapeutics.

Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial

Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months after a low-dose (5 mcg) booster.

Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study

Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) shared topline data from an ongoing Phase 1/2/3 trial evaluating the ARCT-154, a self-amplifying mRNA COVID-19 vaccine candidate. Results from the efficacy analysis have been submitted to the Vietnam Ministry of Health by Vinbiocare on April 13 and shared with Arcturus in parallel with this filing. The Phase…

The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study

The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Get all your
news in one place.

100's of premium titles.
One news app.

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 vaccine candidate as a booster.

Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

379,787 stories

140,227 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play